Immune complexes in ovarian cancer

Immune complexes have been assayed in ovarian cancer with a polyethylene-glycol (P.E.G.) precipitation assay and a Clq solid-phase assay. Significantly higher levels of immune complexes were detected in patients in relapse compared with those in remission. Remission values were within the range obtained for a control group. Evidence was produced that immune-complex levels rise before the clinical detection of relapse, and it is suggested that the P.E.G. assay could be a useful marker of disease progress.